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The pH sensitivity of benzodiazepine binding suggests that a histidine residue may be present in, or close 
to the benzodiazepine binding site. This was confirmed by the selective modification of histidine residues 
using diethyl pyrocarbonate which was found to block both benzodiazepine and p-carboline binding. In 
order to assess whether this histidine residue is located in or adjacent to the benzodiazepine and p-carboline 
binding sites, experiments were performed using either benzodiazepine or /I-carboline to protect against 
diethyl pyrocarbonate treatment. It was found that benzodiazepine agonists, but not propyl p-carboline pro- 
tect the benzodiazepine binding sites from diethyl pyrocarbonate modification. 
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1. INTRODUCTION 
Benzodiazepines and ,&carbolines can modulate 
the GABAergic transmission by binding to the Bdz 
receptor located on the multisubunit Bdz-GABA A 
receptor-chloride channel complex. Amongst Bdz 
and ,&-carbolines three classes of ligands have been 
characterised: (i) agonists, enhancing the 
GABAergic transmission; (ii) inverse agonists 
diminishing GABAergic transmission; and (iii) an- 
tagonists, blocking the effects of both agonists and 
inverse agonists by competitive inhibition [l]. It is 
established that DEP blocks the Bdz [2-41 and p- 
carboline binding to the Bdz-GABA A receptor- 
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chloride channel complex without acting on the 
other binding sites [S]. Flurazepam, a Bdz agonist, 
protects the Bdz and ,&carboline binding from 
DEP treatment [5], indicating that this reagent acts 
on an amino acid residue either in the Bdz binding 
site or its surroundings. This action of DEP has 
been attributed to modification of either a 
histidine or a tyrosine residue [5,6]. 
We present here further evidence that a histidine 
residue is located near or at the Bdz binding site as 
shown by the pH dependency of Bdz antagonist 
Ro 15-1788 binding. Furthermore, the antagonist 
B-CCP does not protect Ro 15-1788 binding from 
DEP modification, whereas the Bdz agonist Flu 
does. 
2. MATERIALS AND METHODS 
[ZV-methyl-3H]Ro 15-1788 (87 Ci/mmol) and 
[ethyl-2-3H]ethyl-&carboline-3-carboxylate (50 Ci/ 
mmol) were from New England Nuclear. [N- 
methyl-3H]Flunitrazepam (65 Ci/mmol) was from 
CEA, Saclay, France. Clonazepam, Flu and 
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Ro 15-1788 were kindly provided by Dr Willy 
Haefely, Hoffmann-La Roche, Basel. B-CCM and 
B-CCP were gifts from Dr Robert H. Dodd, ICSN 
CNRS Gif-sur-Yvette. Absolute DEP from Fluka 
was stored at 4°C and diluted 34-fold in ethanol 
just before use. All buffers, incubations and rins- 
ing were at 4°C unless otherwise stated. The Tris- 
phosphate buffer was prepared by adjusting the 
pH of a 50 mM Tris base solution with H3P04. 
Membrane preparation and [3H]ligand binding 
were performed as described [7]. Briefly male 
Wistar rats (200-250 g) were decapitated and the 
cerebral cortex dissected, homogenised (Poly- 
tron + Potter Elvehjem) in 50 mM Tris-HCl, pH 
7.4 (8.33 ml/g fresh tissue), and centrifuged for 
3 min at 400 x g. The supernatant was centrifuged 
for 20 min at 20000 x g and the pellet was 
resuspended in Tris-HCl (6 ml/g original tissue) 
and recentrifuged for 20 min at 20000 x g. The 
resulting pellet was again suspended, under the 
same conditions, frozen and stored at -30°C. 
Protein was estimated by the method of Lowry et 
al. [8]. For binding experiments, membranes were 
diluted (75-1OOpg protein/ml) in the indicated 
buffer at the required pH (the pH of the incuba- 
tion medium remained unchanged after adding 
membranes), and incubated for 1 h with ligands in 
a total volume of 1 ml. Non-specific binding was 
determined at each pH in the presence of 1 PM 
clonazepam. Incubations were stopped by adding 
3 ml of ice cold incubation buffer to each tube and 
filtering under vacuum through Whatman GF/B 
glass fiber filters. The tube was rinsed once and the 
filter 3 times with 3 ml ice cold buffer. Bound 
radioactivity retained on the filters was counted in 
10 ml of Aquasol scintillation solution with an 
LKB Wallace 1215 Rackbeta 2 counter. 
Modification by DEP and protection ex- 
periments were performed essentially as in [5]. 
Membranes were diluted IO-fold in 20 mM sodium 
phosphate, pH 6, buffer containing 0.2 M NaCl, 
centrifuged 10 min at 29000 x g, and the pellet was 
resuspended in the same buffer at l-2 mg pro- 
tein/ml. For protection experiments, ligand at a 
final concentration of 1 PM was preincubated with 
the membranes for 5 min at 20°C before adding 
DEP. DEP was added at a final concentration of 
1 mM, and after a 15 min incubation at 2O”C, the 
reaction was stopped by a 1Qfold dilution in ice 
cold 50 mM Tris-HCl, pH 7.5, followed by a 
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10 min centrifugation at 29000 x g and the pellet 
was resuspended in 35 ml of Tris-HCl buffer. This 
was repeated 6 times to remove remaining DEP 
and protective ligands. The final resuspension was 
made in 18 ml Tris-HCl, and the treated mem- 
branes were tested for [3H]Ro 15-1788 binding as 
described. Control membranes were treated in an 
identical manner but without the addition of DEP. 
3. RESULTS 
3.1. pH studies 
The pH sensitivity of [3H]Ro 15-1788 binding at 
a final concentration of 0.8 nM is shown in fig. 1. 
Maximum binding occurred at pH 7.5, with a 57% 
decrease at pH 5.5 and a 55% decrease at pH 10.5. 
Since Ro 15-1788 has no pKa in this pH range 
(Fleury, B., personal communication, and [9]), 
changes in its binding can be attributed to 
modification of its binding sites. 
The reversibility of this pH effect on Bdz 
binding was tested by diluting the membranes 
IO-fold in Tris-phosphate buffer at pH 5.5, 7.5 and 
10.5. At different incubation times aliquots were 
taken, centrifuged for 10 min at 29000 x g and the 
pellet resuspended in Tris-phosphate buffer, pH 
7.5 (75-100 pg protein/ml), was tested for [3H]Flu 
I , , , . 
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Fig.1. Specific binding of 0.8 nM of [3H]Ro 15-1788 in 
50 mM T&phosphate buffer at pH from 5.5 to 10.5 
expressed in % of the specific binding at pH 7.5. The 
results are the means of two experiments. Non-specific 
binding was determined in the presence of 1 ,LLM 
clonazepam and was below 3% of the total binding. 
Assays were carried out in triplicate. Buffer of the same 
pH was used to incubate and to rinse the filters. 
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and [3H]B-CCE binding as described. No decrease 
in binding with time was observed, indicating that 
no denaturation of Bdz and ,&carboline binding 
sites occurred at either pH 5.5 or pH 10.5. The pH 
sensitivity does not therefore result from a 
denaturation of the Bdz receptor macromolecule. 
Increasing the ionic strength of binding buffer, 
by adding 0.45 M NaCl, which is known to 
diminish electrostatic interactions between surface 
residues of proteins [lo], did not change the pH 
dependency of the binding between pH 7.5 and 5.5 
(not shown). 
Binding constants of [‘H]Ro 15-1788 at pH 7.5 
and 5.5 in Tris-phosphate buffer were investigated 
by saturation experiments (fig.2). A 46% decrease 
in B,,, (number of sites) was seen between pH 7.5 
and pH 5.5, which is in good agreement with the 
57% decrease found for ([‘H]Ro 15-1788) = 
0.8 nM binding (fig.1). No effect on & (affinity) 
was observed. 
3.2. Modification experiments 
Incubating membranes at pH 6 with 1 mM DEP 
for 15 min at 20°C was found to block 67% of 
t3H]Ro 15-1788 binding sites without changing the 
& (figs 3 and 4). 
Data pertaining to protection by Flu are shown 
in fig.3. No decrease in B,,, was observed when 
1 PM flunitrazepam was included in the incuba- 
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Fig.4. Eadie-Hofstee analysis of [3H]Ro 15-1788 
binding to: (0) control membranes; (0) DEP-treated 
membranes; (0) DEP + B-CCP-treated membranes; (A) 
DEP + B-CCM-treated membranes; (m) membranes 
incubated with B-CCP; (A) membranes incubated with 
B-CCM. (For clarity: line 1 is solid and line 6 broken.) 
For protection experiments 1 pM B-CCM or 1 pM B- 
CCP were preincubated 5 min at 20°C before DEP 
addition. This experiment was repeated three times with 
Fig.2. Eadie-Hofstee analysis of [3H]Ro 15-1788 
binding at pH 7.5 (A) and at pH 5.5 (A) in Tris- 
phosphate buffer. Each .point was made in duplicate. 
Buffer of the same pH was used to incubate and to rinse 
the filters. similar results. 
1 CONTROL 
2 DEP 
3 DEP+FLU 
4 FLU 
.05 .I .15 B/F 
Fig.3. Eadie-Hofstee analysis of [3H]Ro 15-1788 
binding to: (0) control membranes; (0) DEP-treated 
membranes; (*) DEP + Flu-treated membranes; (0) 
membranes incubated with Flu. For protection 1 PM Flu 
was incubated 5 min before adding DEP. Modification 
by 1 mM DEP was performed 15 min at 20°C. 
[3H]Ro 15-1788 binding was tested after modification. 
This experiment was repeated four times with similar 
results. 
tion, confirming the protective potency of Bdz 
agonists. A control consisting of membranes in- 
cubated with Flu alone showed that the ligand was 
; “, W;TROL 
3 0 DEP+B-CCP 
4 A DEP+B-CCM 
5 n B-CCP 
6 A B-CCM 
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completely removed by the washing procedures. 
Data pertaining to protection by fl-carbolines 
are shown in fig.4. Under the same conditions B- 
CCP (1 ,LLM) did not protect the Bdz binding site 
against DEP modification a 67% decrease in B,,, 
being observed in either its presence or its absence. 
In addition 1 ,uM B-CCM gave only a very slight 
protection (58% decrease in B,,, as opposed to a 
67% decrease for DEP or DEP + B-CCP). The 
slight increase in Kd observed when P-carbolines 
were present was probably due to the incomplete 
removal of the ligands as a similar increase was 
found with control membranes incubated with B- 
CCP alone. 
Thin layer chromatography and spectro- 
photometry were used to verify that DEP did not 
react with B-CCP, B-CCM or Flu. 
4. DISCUSSION 
In this study we were specifically interested in in- 
vestigating modifications of the Bdz binding site 
and it was therefore considered important to use 
an antagonist, [3H]Ro 15-1788, for binding, in- 
stead of an agonist. Agonists binding is far more 
susceptible than antagonists binding to allosterical 
modulations [l] and is therefore more sensitive to 
modifications of the Bdz receptor macromolecule 
occurring away from the binding site. 
The pH sensitivity of [3H]Ro 15-1788 binding 
was found to be similar to that previously reported 
for the agonist [‘Hldiazepam [ll]. Since we have 
shown that the pH effect is reversible and is not 
therefore caused by receptor denaturation, we 
have concluded that this pH sensitivity is the result 
of changes in the Bdz binding site probably caused 
by the protonation or deprotonation of amino acid 
residues at or near the site. The decrease in binding 
observed between pH 7.5 and 10.5 could be due to 
numerous amino acid residues since many of them 
have pK, values in this range. Histidine, however, 
is the only amino acid which has a side chain pKa, 
in solution, of between pH 7.5 and 5.5. In addition 
the absence of shift in acidic pH sensitivity with in- 
creased ionic strength, indicates that the pK, of the 
amino acid residue, on which protonation occurs, 
is not very different from its value in solution. The 
most likely explanation for the decrease in binding 
observed over this pH range therefore is that it is 
caused by the protonation of a histidyl residue. 
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The protonation of this putative histidine 
residue results in a decrease of B,,, (fig.2), in- 
dicating that the residue is near to or in the Bdz 
binding site, as the modification of a residue fur- 
ther away from the site would be expected to 
disturb it less and to result in a Kd rather than a 
B max modification. 
The results obtained with DEP also support the 
presence of a histidine residue in the Bdz binding 
site or near to it. DEP, under the conditions used, 
is a highly selective reagent for histidine residues 
[ 121 and this coupled with the observed pH effects, 
makes its action through a tyrosine residue very 
unlikely. DEP treatment of the Bdz receptor com- 
plex has been shown previously to modify the 
binding of the agonist [3H]diazepam. The fact that 
we have obtained similar results using the an- 
tagonist [3H]Ro 15-1788, strongly indicates that 
the reagent modifies the Bdz binding site itself and 
is not acting at a site which could allosterically af- 
fect agonists binding. The absence of protection by 
/J-carbolines from DEP treatment implies that the 
histidine residue, although important for ,&- 
carboline binding [5], is not directly part of the p- 
carboline binding site. 
The protection afforded by Bdz agonists Flu and 
flurazepam can be interpreted in at least two ways. 
The histidine residue modified by DEP may be 
part of the Bdz binding site and thus would be pro- 
tected sterically by Bdz binding. This residue may 
therefore be a part of the Bdz binding site which is 
distinct from the ,L?-carboline binding site. Alter- 
natively, the histidine residue may be in a region of 
the Bdz receptor macromolecule which allosterical- 
ly interacts with the Bdz binding site. In contrast to 
the binding of antagonists (B-CCP) or partial in- 
verse agonists (B-CCM), agonist binding might 
stabilise the receptor in a conformation in which 
DEP is no longer able to react with the histidine 
residue. 
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